United Therapeutics Corp. Director Raymond Dwek Unloads 3,000 Shares (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) Director Raymond Dwek sold 3,000 shares of the stock on the open market in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $111.41, for a total value of $334,230.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.37% on Friday, hitting $111.31. 569,099 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $51.38 and a 1-year high of $116.65. The stock has a 50-day moving average of $95.60 and a 200-day moving average of $80.57. The company has a market cap of $5.591 billion and a price-to-earnings ratio of 20.15.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Tuesday, October 29th. The company reported $2.98 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter last year, the company posted $2.82 earnings per share. United Therapeutics Corp.’s revenue was up 24.6% compared to the same quarter last year.
A number of research firms have recently commented on UTHR. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $88.21.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.